

Reconciliation of studies included and conclusions with prior systematic reviews and meta-analyses (SRMA)					
Endpoints		Current (August, 2020) PMID 32805168	Giustozzi, 2020	Fuentes, 2019 PMID 31685262	Wongsaengsak, 2019
1	VTE recurrence	↓	↓	↓	↓
	Effect estimates (95% CI)	OR: 0.59 (0.41-0.86)	RR: 0.62 (0.43-0.91)	OR: 0.48 (0.24-0.96)	RR: 0.48 (0.26-0.87)
	Meta-Analysis method	Random-effects model	Random-effects model	Random-effects model	Random-effects model
	Tau ² estimation method	DerSimonian and Laird	Not specified	Not specified	DerSimonian and Laird
	Hartung-Knapp adjustment	No	No	No	No
	Heterogeneity (I ²)	25%	30%	46%	56%
2	Major bleeding	↔	↔	↑	↔
	Effect estimates (95% CI)	OR: 1.34 (0.83-2.18)	RR: 1.31 (0.83-2.08)	OR: 1.70 (1.04-2.78)	RR: 1.55 (0.79-3.04)
	Meta-Analysis method	Random-effects model	Random-effects model	Random-effects model	Random-effects model
	Tau ² estimation method	DerSimonian and Laird	Not specified	Not specified	DerSimonian and Laird
	Hartung-Knapp adjustment	No	No	No	No
	Heterogeneity (I ²)	28%	23%	2%	29%
3	CRNMB	↑	↑	↔	↔
	Effect estimates (95% CI)	OR: 1.65 (1.13-2.42)	RR: 1.65 (1.19-2.28)	OR: 1.82 (0.93-3.55)	RR: 1.80 (0.96-3.38)
	Meta-Analysis method	Random-effects model	Random-effects model	Random-effects model	Random-effects model
	Tau ² estimation method	DerSimonian and Laird	Not specified	Not specified	DerSimonian and Laird
	Hartung-Knapp adjustment	No	No	No	No
	Heterogeneity (I ²)	41%	29%	-	60%
Intervention	DOACs	DOACs	DOACs	DOACs	
Population (Inclusion)	Cancer associated thrombosis	Cancer associated thrombosis	Cancer associated thrombosis	Cancer associated thrombosis	
Studies included ^b	N = 4	N = 4	N = 3	N = 3	
	n = 4	n = 4	n = 3	n = 3	

Summary of important differences^c	Effect sizes were expressed as OR	Addition of CaraVaggio trial	Effect sizes were expressed as OR	Outcomes reported at 12 months for HOKUSAI VTE trial were used in analysis
	Outcomes reported at 12 months for HOKUSAI VTE trial were used in analysis	Effect sizes were expressed as RR Outcomes reported at 6 months for all trials were used in analysis	Difference in the number of events considered for ADAM VTE trial in dalteparin arm (n=2 as opposed to n=3 in previous SRMA)	Difference in the number of events considered for ADAM VTE trial in dalteparin arm (n=3 as opposed to n=2 in previous SRMA)

Notes:

Abbreviations: VTE: venous thromboembolism; CRNMB: clinically relevant non-major bleeding; DOACs: direct oral anticoagulants; CI: confidence interval; OR: odds ratio; RR: risk ratio/relative risk; RCTs: randomized controlled trials

↓: significant decrease; ↑: significant increase; ↔: no significant change;

N: total number of studies included in the systematic review; **n:** number of studies included in the analysis

Trials included

Color	Trial name	Author	Year
●	HOKUSAI-VTE	Raskob	2018
●	SELECT-D	Young	2018
●	ADAM-VTE	McBane II	2019
●	CaraVaggio	Agnelli	2020